Pfizer's Covid vaccine 73.2% effective in kids under 5, shows new data

The updated data showed 13 children had Covid, at least seven days after receiving a third dose of the Pfizer-BioNTech COVID-19 vaccine, compared with 21 cases among those who received a placebo

vaccine, Covid vaccine, Pfizer vaccine
The updated data released on Tuesday showed 13 children had COVID-19, at least seven days after receiving a third dose of the Pfizer-BioNTech COVID-19 vaccine, compared with 21 cases among those who received a placebo.
Reuters
2 min read Last Updated : Aug 23 2022 | 7:39 PM IST
Pfizer Inc and BioNTech's vaccine was 73.2% effective in preventing COVID-19 among children aged 6 months through 4 years, new data from the companies showed on Tuesday, two months after the U.S. rollout of the shots began for that age group.
 
The Pfizer-BioNTech vaccine was authorised for children under 5 years of age in June, based on data that showed the vaccine generated a similar immune response as in older age groups.
 
An early analysis based on 10 symptomatic COVID-19 cases in the study had suggested a vaccine efficacy of 80.3%. But experts had warned that the data was preliminary due to a low number of symptomatic cases.
 
The updated data released on Tuesday showed 13 children had COVID-19, at least seven days after receiving a third dose of the Pfizer-BioNTech COVID-19 vaccine, compared with 21 cases among those who received a placebo.
 
Most cases were caused by the Omicron BA.2 variant that was dominant in March and April, when the study was conducted.
Pfizer and BioNTech also said they were preparing an application seeking U.S. authorization for a so-called bivalent vaccine that targets the BA.4/BA.5 subvariants of Omicron for children under 12.
 
The companies on Monday applied for U.S. authorization of the bivalent vaccine as a booster in those aged 12 and above.
Pfizer said a pediatric trial for the Omicron-adapted vaccine would begin in the fall, and it would work with regulators to determine what data was needed for authorization.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :PfizerCoronavirus Vaccinechildren

Next Story